
==== Front
Cancer Med
Cancer Med
10.1002/(ISSN)2045-7634
CAM4
Cancer Medicine
2045-7634
John Wiley and Sons Inc. Hoboken

10.1002/cam4.70233
CAM470233
Correction
Correction
Correction to: Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
14 9 2024
9 2024
14 9 2024
13 17 10.1002/cam4.v13.17 e70233© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

10.1002/cam4.7408 source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:14.09.2024
==== Body
pmcShao Z, et al., Cancer Med. 2024 Aug;13(15):e7408. https://doi.org/10.1002/cam4.7408. PMID: 39136200; PMCID: PMC11320080

We requested post‐publication to add the following line after the first line in the acknowledgment section:

We also thank DMC chair Prof. Xichun Hu, DMC member Prof. Jin Zhang, Prof. Shusen Wang, Prof. Renbing Liu, and Prof. Chen Yao for their contributions to the trial.

We apologize for this error.
